Comparative Pharmacology
Head-to-head clinical analysis: CEPTAZ versus PANIXINE DISPERDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPTAZ versus PANIXINE DISPERDOSE.
CEPTAZ vs PANIXINE DISPERDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
None Documented
None Documented
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic